MedicineWorld.Org
Your gateway to the world of medicine
Home
News
Cancer News
About Us
Cancer
Health Professionals
Patients and public
Contact Us
Disclaimer

Medicineworld.org: Erlotinib improves survival as first-line therapy

Back to lung cancer blog Blogs list Cancer blog  


Subscribe To Lung Cancer Blog RSS Feed  RSS content feed What is RSS feed?

Erlotinib improves survival as first-line therapy




For patients with advanced lung cancer whose tumors carry EGFR activating mutations, first-line therapy with erlotinib nearly tripled progression-free survival in comparison to a standard chemotherapy combination, show results from the first prospective Phase-III study to report findings in this setting.

The new results from the OPTIMAL trial were reported at the 35th Congress of the European Society for Medical Oncology (ESMO) in Milan, Italy.

"Erlotinib is very effective and well tolerated in advanced NSCLC patients who harbor EGFR activating mutations. It is 2 to 3 times more effective than doublet chemotherapy," said study leader Professor Caicun Zhou of Shanghai Pulmonary Hospital, Tongji University, China.



Erlotinib improves survival as first-line therapy

The OPTIMAL study included 165 patients whose lung cancer carried mutations activating the Epithelial Growth Factor Receptor (EGFR). Participants had not received systemic therapy for their cancer.

Of these patients, 83 were randomly assigned to receive erlotinib 150 mg/day, and 82 patients were assigned to receive a 'doublet' combination chemotherapy of gemcitabine and carboplatin. The primary endpoint of the study was progression-free survival.

In his presentation at the ESMO Congress, Prof Zhou reported that the median progression-free survival in the erlotinib arm was 13.1 months, in comparison to 4.6 months for the chemotherapy arm of the study. The objective response rate with erlotinib was 83%, in comparison to 36% for gemcitabine plus carboplatin. 31 patients in the erlotinib arm are still under study and progression free in comparison to only 1 in the chemotherapy arm.

"OPTIMAL is the first reported prospective Phase-III study to confirm the role of erlotinib in advanced NSCLC patients with EGFR activating mutations," Prof Zhou said. "It does much better than the standard doublet chemotherapy and so we should start erlotinib therapy as soon as possible after the diagnosis of advanced NSCLC with EGFR activating mutations," he added.

Safety analyses showed lower rates of adverse events with erlotinib than with chemotherapy, the scientists report.

Also at the ESMO Congress, Professor Yi-long Wu from Guangdong General Hospital (GGH) & Guangdong Academy of Medical Sciences in China reported the first biomarker results from the study. This analysis aimed to evaluate the impact on various biomarkers with survival among the patient population.

"Detailed biomarker analysis did not identify additional markers that could be used to further optimize therapy decisions. It was observed that patients who had exon 19 deletions in EGFR had longer progression-free survival with erlotinib than those with L858R mutations and only one patient had an EGFR T790M mutation, and remained progression-free for only 0.62 months," Prof Wu said.

The results of the OPTIMAL trial have implications for clinical practice, commented Dr Federico Cappuzzo, Director of Medical Oncology at Ospedale Civile in Livorno, Italy.

"These data, combined with data coming from another four large Phase-III studies comparing chemotherapy versus gefitinib, another orally available EGFR tyrosine kinase inhibitor (EGFR-TKI), confirmed that erlotinib or gefitinib represent the best therapeutical option we can offer today as front-line treatment in metastatic NSCLC with activating EGFR mutations".

Dr Cappuzzo noted that all studies so far in this setting have been conducted in Asian populations. A confirmatory study in Caucasian patients is currently ongoing.


Posted by: Scott    Source




Did you know?
For patients with advanced lung cancer whose tumors carry EGFR activating mutations, first-line therapy with erlotinib nearly tripled progression-free survival in comparison to a standard chemotherapy combination, show results from the first prospective Phase-III study to report findings in this setting.

Medicineworld.org: Erlotinib improves survival as first-line therapy

Main Page| Cancer blog| Cancer blogs list| Lung cancer blog| Colon cancer blog| Prostate cancer blog| Breast cancer blog| Diabetes watch blog| Heart watch blog| Allergy blog| Bladder cancer blog| Cervical cancer blog| Colon cancer news blog| Diabetes news blog| Esophageal cancer blog| Gastric cancer blog| Health news blog| Heart news blog| Infectious disease blog| Kidney watch blog| Lung disease blog| Lung cancer news blog| Mesothelioma blog| Neurology blog| Breast cancer news blog| OBGYN blog| Ophthalmology blog| Ovarian cancer blog| Cancer news blog| Pancreas cancer blog| Pediatrics blog| Prostate cancer news blog| Psychology blog| Research blog| Rheumatology blog| Society news blog| Uterine cancer blog| Weight watch blog|

Copyright statement
The contents of this web page are protected. Legal action may follow for reproduction of materials without permission.